Metopirone Esteve Pharmaceuticals (Metyrapone)

Metyrapone inhibits the adrenal enzyme 11‑beta‑hydroxylase, blocking the final step of cortisol synthesis. This reduces cortisol output and leads to accumulation of precursor steroids that can be measured for diagnostic purposes or used therapeutically to control hypercortisolism.

The dosage of Metopirone is individualized and must be prescribed by a qualified healthcare professional. The prescriber determines the amount, frequency, and duration based on the specific indication and patient response.

Safety data for metyrapone during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To order Metopirone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The most common alternative for cortisol suppression is ketoconazole, another steroidogenesis inhibitor. Compared with ketoconazole, metyrapone has a more selective action on 11‑beta‑hydroxylase and may be preferred when liver toxicity is a concern, although individual response varies.

Metopirone should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture and direct sunlight to maintain stability and potency.

Metopirone is administered orally, typically as tablets or capsules, and should be taken according to the prescribing clinician’s instructions, usually with or without food as directed.

Serious risks include adrenal crisis from sudden cortisol withdrawal, severe hypertension, and significant electrolyte disturbances such as hypokalemia. Patients should be monitored closely for these events, especially during dose changes.

Metopirone is contraindicated in individuals with known hypersensitivity to metyrapone, severe uncontrolled hypertension, or significant liver impairment. Caution is also advised for patients with pre‑existing electrolyte abnormalities.